Advertisement

Neue Ergebnisse zur Rolle der Chemotherapie beim Prostatakarzinom

  • A. Yagoda

Zusammenfassung

Weniger als 10%–20% der Patienten mit fortgeschrittenem Adenokarzinom der Prostata profitieren von einer Chemotherapie, und eine vollständige Remission (CR) wird durch diese Therapie nicht erreicht. Diese Zahlen verdeutlichen die eingeschränkte Wirksamkeit einer Zytostase bei diesem Tumor. Randomisierte Phase- III-Studien zeigten bei Patienten, die auf eine Chemotherapie ansprachen, keine signifikant höhere Überlebensdauer.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Braich T, Ahmann FR, Garewal HS, Robertone A, Salmon SE (1986) Phase II trials of 4’deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer. Invest New Drugs 4: 193–196PubMedGoogle Scholar
  2. 2.
    Bryan C, Munn R, John W, Macdonad J, Marshall ME (1989) Treatment of hormone refractory stage D prostate carcinoma with CHIP (NSC #256927). Proc Am Soc Clin Oncol 8: 148Google Scholar
  3. 3.
    Bui NB, Chauvergne J, Brunei R, Richaud P, Hoerni B, LaGarde C, LeGuillou M (1986) Cancer de la prostate metastatique: etude de phase II du spirogermanium (NSC 192965). Bull Cancer 73: 201–205Google Scholar
  4. 4.
    Craig J, Crawford E (1989) Phase II trial of amonafide in advanced prostate cancer: a Southwest Oncology Group study. Proc Am Soc Clin Oncol 8: 147Google Scholar
  5. 5.
    Curley T, Engstrom CV, Scher H, Dershaw D, Yagoda A, Nisselbaum J, Eisenberger M (1989) Phase II trial of trimetrexate (TMTX) in hormone refractory bidimensionally measurable (BDM) prostate cancer (PC). Proc Am Soc Clin Oncol 8: 140Google Scholar
  6. 6.
    Dexeus F, Logothetis CJ, Samuels ML, Hossan E, Von Eschenbach AC (1985) Continuous infusion of vinblastine for advanced hormone refractory prostate cancer. Cancer Treat Rep 69: 885–886PubMedGoogle Scholar
  7. 7.
    Dexeus FH, Logothetis C, Samuels M, Hossan B (1986) Phase II study of spirogermanium in metastatic prostate cancer. Cancer Treat Rep 70: 1129–1130PubMedGoogle Scholar
  8. 8.
    Dulbul MA, Huben RP, Murphy GP, National Prostatic Cancer Treatment Group (1986) In- terferon-beta treatment of metastaic prostate cancer. J Surg Oncol 33: 231–235CrossRefGoogle Scholar
  9. 9.
    Eisenberger MA, Abrams JS (1988) Chemotheray for prostatic carcinoma. Semin Urol 6: 303–310PubMedGoogle Scholar
  10. 10.
    Ghosn M, Droz IP, Mahjoubi M, Theodore C, Azab M, Ostronoff M (1989) Phase II trial of ifosfamide (IFO) in hormone refractory metastatic cancer of the prostate (HRMCP). Proc Amer Soc Clon Oncol 8: 141Google Scholar
  11. 11.
    Herr HW, Warreil RP, Burchenal JH (1986) Phase I trial of alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis guanylhydrazone (MGBG) in patients with advanced prostatic cancer. Urology 28: 508–512PubMedCrossRefGoogle Scholar
  12. 12.
    Marshall ME, Butler K, Hermansen D, McRoberts W (1989) Treatment of stage D hormone refractory carcinoma of prostate with coumarin (1,2-benzopyrone) and Cimetidine. Proc Am Soc Clin Oncol 8: 135Google Scholar
  13. 13.
    Moore MR, Troner MB, DeSimone P, Birch R, Irwin L (1986) Phase II evaluation of weekly cisplatin metastatic hormone resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70: 541–543PubMedGoogle Scholar
  14. 14.
    Moore MR, Graham SD, Birch R, Irwin L (1987) Phase II evaluation of mitoguazone in metastatic hormone resistant prostate cancer: a Southeastern Cancer Group trial. Cancer Treat Rep 71: 89–90PubMedGoogle Scholar
  15. 15.
    Natale RB, Yagoda A, Watson RC, Stover D (1980) Phase II trial of neocarcinostatin in patients with bladder and prostatic cancer: toxicity of a 5-day bolus schedule. Cancer 45: 2836–2838PubMedCrossRefGoogle Scholar
  16. 16.
    Natale RB, Yagoda A, Watson RC (1982) Phase II trial of AMSA (4’[9-acridinylamino methanesulfon-m-anisidide]). Cancer Treat Rep 66: 208–212PubMedGoogle Scholar
  17. 17.
    O’Bryan RM, Baker LH, Gottlieb JA, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE et al. (1977) Pose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948PubMedCrossRefGoogle Scholar
  18. 18.
    Osborne CK, Drelichman A, Von Hoff DD, Crawford ED (1983) Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 67: 11332–1135Google Scholar
  19. 19.
    Ragahavan D (1988) Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15: 371–389Google Scholar
  20. 20.
    Scher HI, Yagoda A (1987) Clinical trials in prostatic cancer: methodologies and controverses. In: Bruce AW, Trachtenberg J (eds) Adenocarcinoma of the prostate. Springer, London, pp 197–219CrossRefGoogle Scholar
  21. 21.
    Scher HI, Yagoda A, Watson RC, Sogani P, Whitmore WF (1984) Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 132: 1099–1102Google Scholar
  22. 22.
    Scher HI, Yagoda A, Ahmed T, Watson RC (1985) Methyl glyoxal-bis (guanylhydrazone) (MGBG): an active drug in prostate cancer. J Clin Oncol 3: 224–228PubMedGoogle Scholar
  23. 23.
    Scher HI, Sternberg CN, Heston WDW, Watson RC, Niedzwiecki D, Hollander P, Yagoda A (1986) Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer Chemother Pharmacol 18: 14–26CrossRefGoogle Scholar
  24. 24.
    Scher HI, Curley T, Geller N, Heston W, Dershaw D, Chan E, Nisselbaum WDW et al. (1987) Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover. Cancer Treat Rep 71: 887–893PubMedGoogle Scholar
  25. 25.
    Scher H, Smart-Curley T, Heston WDW, Reuter V, Sternberg CN, Dershaw D, Herr H et al. (1988) Phase I —II trial of alpha-difluoromethylornithine (DFMO; MDL 71 782) and mitoguazone in hormone refractory prostatic cancer (PC). Proc Am Assoc Cancer Res 19: 191Google Scholar
  26. 26.
    Scher HI, Smart-Curley T, Dershaw DD, Watson RC, Nisselbaum J, Schwartz M, Yagoda A (1989) Cytotoxic chemotherapy for advanced cancer of the prostate: Memorial Sloan-Kettering Cancer Center experience. In: Johnson DC, Logothetis CJ, Von Eschenbach AC (eds) Systemic therapy for genitourinary cancer. Yearbook Medical Publ, Chicago, pp 228–232Google Scholar
  27. 27.
    Torti FM, Shortliffe LD, Carter SK, Hannigan JF, Aston D, Lum BL, Williams RD et al. (1985) Randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine unresponsive metastatic prostatic carcinoma. Cancer 56: 2280–2284CrossRefGoogle Scholar
  28. 28.
    Torti FM, Lum B, Freiha FS, Loo RK (1989) Approaches to advanced prostate cancer at Stanford University. In: Johnson DC, Logothetis CJ, Von Eschenbach AC (eds) Systemic therapy for genitourinary cancer. Yearbook Medical Publ, Chicago, pp 239–244Google Scholar
  29. 29.
    Trump DL, Loprinzi CL (1984) Phase II trial of etoposide in advanced prostate cancer. Cancer Treat Rep 68: 1195–1196.PubMedGoogle Scholar
  30. 30.
    Walther PJ, Williams SD, Troner M, Greco FA, Birch R, Einhorn LH, Southeastern Cancer Study Group (1986) Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 70: 771–772PubMedGoogle Scholar
  31. 31.
    Xavier A (1989) Prostate cancer presenting with pulmonary manifestations. Proc Am Soc Clin Oncol 8: 138Google Scholar
  32. 32.
    Yagoda A (1973) Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma. Cancer 32: 1131–1140PubMedCrossRefGoogle Scholar
  33. 33.
    Yagoda A (1983) Cytotoxic agents in prostate cancer: an enigma. Semin Urol 1: 311–320PubMedGoogle Scholar
  34. 34.
    Yagoda A, Watson RC, Barzell WE, Sogani P, Grabstald H, Whitmore WF (1979) A critical analysis of response criteria in patients with prostate cancer treated with cis-diaminedichloride platinum II. Cancer 44: 1563–1566PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. Yagoda
    • 1
  1. 1.Department of Urology and Hematology/OncologyUniversity Medical College, New York Hospital-CornellNew YorkUSA

Personalised recommendations